Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Februar 2012 17:30 ET | Quelle: NeurogesX

NeurogesX Provides Update on Qutenza(R) (Capsaicin) 8% Patch for New Indication to Treat HIV-PN Following FDA Advisory Committee Review

SAN MATEO, Calif., Feb. 9, 2012 (GLOBE NEWSWIRE) -- NeurogesX (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
09. Februar 2012 07:01 ET | Quelle: NeurogesX

NeurogesX' Stock Trading Halted Today

SAN MATEO, Calif., Feb. 9, 2012 (GLOBE NEWSWIRE) -- NeurogesX Inc., a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management,...
03. Februar 2012 16:15 ET | Quelle: NeurogesX

NeurogesX Grants Equity Awards Under Its 2011 Inducement Stock Plan

SAN MATEO, Calif., Feb. 3, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
01. Februar 2012 08:45 ET | Quelle: NeurogesX

NeurogesX, Inc. Announces $3.0 Million Private Placement

SAN MATEO, Calif., Feb. 1, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today...
03. Januar 2012 10:00 ET | Quelle: NeurogesX

NeurogesX Appoints Ronald Martell President and Chief Executive Officer

SAN MATEO, Calif., Jan. 3, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today...
15. Dezember 2011 14:40 ET | Quelle: NeurogesX

NeurogesX Confirms FDA Advisory Committee to Review sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)

SAN MATEO, Calif., Dec. 15, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today...
14. November 2011 16:10 ET | Quelle: NeurogesX

NeurogesX Receives FDA Acceptance for Review of sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)

SAN MATEO, Calif., Nov. 14, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today...
09. November 2011 16:28 ET | Quelle: NeurogesX

NeurogesX to Present at Lazard Capital Markets 8th Annual Healthcare Conference

SAN MATEO, Calif., Nov. 9, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced...
08. November 2011 07:25 ET | Quelle: NeurogesX

NeurogesX to Hold Conference Call Today at 8:30 a.m. ET to Discuss NGX-1998 Phase 2 Clinical Study Results

SAN MATEO, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced it...
08. November 2011 07:20 ET | Quelle: NeurogesX

NeurogesX Reports Positive Phase 2 Results for NGX-1998 for Treatment of Postherpetic Neuralgia

Study Results Support 5 Minute Application of Topical Liquid Capsaicin Formulation Conference Call Today at 8:30am (ET) SAN MATEO, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc....

Vorherige Seite

Nächste Seite